108 related articles for article (PubMed ID: 32938954)
1. Acute toxicity analysis of Disarib, an inhibitor of BCL2.
Sharma S; Varsha KK; Kumari S; Gopalakrishnan V; Jose AE; Choudhary B; Mantelingu K; Raghavan SC
Sci Rep; 2020 Sep; 10(1):15188. PubMed ID: 32938954
[TBL] [Abstract][Full Text] [Related]
2. A novel inhibitor of BCL2, Disarib abrogates tumor growth while sparing platelets, by activating intrinsic pathway of apoptosis.
Vartak SV; Hegde M; Iyer D; Gaikwad S; Gopalakrishnan V; Srivastava M; Karki SS; Choudhary B; Ray P; Santhoshkumar TR; Raghavan SC
Biochem Pharmacol; 2016 Dec; 122():10-22. PubMed ID: 27693384
[TBL] [Abstract][Full Text] [Related]
3. Acute toxicity analysis of an inhibitor of BCL2, Disarib, in rats.
Sharma S; Varsha KK; Ray U; Siddiqua H; Jose AE; Muninarasimaiah S; Raghavan SC; Choudhary B
Sci Rep; 2021 May; 11(1):9982. PubMed ID: 33976278
[TBL] [Abstract][Full Text] [Related]
4. Novel BCL2 inhibitor, Disarib induces apoptosis by disruption of BCL2-BAK interaction.
Vartak SV; Iyer D; Santhoshkumar TR; Sharma S; Mishra A; Goldsmith G; Srivastava M; Srivastava S; Karki SS; Surolia A; Choudhary B; Raghavan SC
Biochem Pharmacol; 2017 May; 131():16-28. PubMed ID: 28223017
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain.
Iyer D; Vartak SV; Mishra A; Goldsmith G; Kumar S; Srivastava M; Hegde M; Gopalakrishnan V; Glenn M; Velusamy M; Choudhary B; Kalakonda N; Karki SS; Surolia A; Raghavan SC
FEBS J; 2016 Sep; 283(18):3408-37. PubMed ID: 27444341
[TBL] [Abstract][Full Text] [Related]
6. Integrated Transcriptome and Metabolomic Analysis Reveal Anti-Angiogenic Properties of Disarib, a Novel Bcl2-Specific Inhibitor.
Manjunath M; Swaroop S; Pradhan SS; Rao K R; Mahadeva R; Sivaramakrishnan V; Choudhary B
Genes (Basel); 2022 Jul; 13(7):. PubMed ID: 35885991
[TBL] [Abstract][Full Text] [Related]
7. Block Copolymer Encapsulation of Disarib, an Inhibitor of BCL2 for Improved Chemotherapeutic Potential.
Joy R; Siddiqua H; Sharma S; Raveendran M; John F; Hassan PA; Gawali SL; Raghavan SC; George J
ACS Omega; 2023 Oct; 8(43):40729-40740. PubMed ID: 37929147
[TBL] [Abstract][Full Text] [Related]
8. Pyrazole (1, 2-diazole) induce apoptosis in lymphoma cells by targeting BCL-2 and BCL-XL genes and mitigate murine solid tumour development by regulating cyclin-D1 and Ki-67 expression.
Vishnu WK; Abeesh P; Guruvayoorappan C
Toxicol Appl Pharmacol; 2021 May; 418():115491. PubMed ID: 33737021
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of edotecarin in breast carcinoma models.
Ciomei M; Croci V; Stellari F; Amboldi N; Giavarini R; Pesenti E
Cancer Chemother Pharmacol; 2007 Jul; 60(2):229-35. PubMed ID: 17089166
[TBL] [Abstract][Full Text] [Related]
10. Efficient T3P
Kamath PR; Sunil D; Das S; Abdul Salam AA; Rao BS
Chem Biol Interact; 2017 Apr; 268():53-67. PubMed ID: 28235427
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor.
Yao HP; Zhuang CM; Zhou YQ; Zeng JY; Zhang RW; Wang MH
Curr Cancer Drug Targets; 2013 Jul; 13(6):686-97. PubMed ID: 23597200
[TBL] [Abstract][Full Text] [Related]
12. In vivo anti-tumour activity of novel Quinazoline derivatives.
Alapati V; Noolvi MN; Manjula SN; Pallavi KJ; Patel HM; Tippeswamy BS; Satyanarayana SV
Eur Rev Med Pharmacol Sci; 2012 Nov; 16(13):1753-64. PubMed ID: 23208959
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of phthalmustine, a new anticancer compound. I. Effect on Dalton's ascitic lymphoma in mice.
Bhattacharya S; Ganguly C; Sanyal U; Das S
Neoplasma; 1994; 41(1):35-8. PubMed ID: 8202193
[TBL] [Abstract][Full Text] [Related]
14. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor action of berberinol thiophosphamide in experimental tumors in mice].
Potopal'skiĭ AI; Shishka GV; Iordan AM
Vopr Onkol; 1974; 20(4):70-5. PubMed ID: 4216155
[No Abstract] [Full Text] [Related]
16. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
17. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer.
Kondratyev M; Kreso A; Hallett RM; Girgis-Gabardo A; Barcelon ME; Ilieva D; Ware C; Majumder PK; Hassell JA
Oncogene; 2012 Jan; 31(1):93-103. PubMed ID: 21666715
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
[TBL] [Abstract][Full Text] [Related]
19. Potentiating apoptosis and modulation of p53, Bcl2, and Bax by a novel chrysin ruthenium complex for effective chemotherapeutic efficacy against breast cancer.
Roy S; Sil A; Chakraborty T
J Cell Physiol; 2019 Apr; 234(4):4888-4909. PubMed ID: 30246261
[TBL] [Abstract][Full Text] [Related]
20. Effects of epithelial growth factor receptor (EGFR) kinase inhibitors on genetically reconstituted mouse mammary glands.
Roth DR; Roman D; Cozens R; Brandt R; Seewald W; Greiner B; Wenger F; Mamom T; Germann PG
Exp Toxicol Pathol; 2003 Nov; 55(4):237-45. PubMed ID: 14703768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
